Illumina Inc
$ 166.21
2.30%
11 Jun - close price
- Market Cap 25,147,574,000 USD
- Current Price $ 166.21
- High / Low $ 166.21 / 160.65
- Stock P/E 30.22
- Book Value 17.61
- EPS 5.50
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.34 %
- 52 Week High 177.22
- 52 Week Low 86.03
About
Illumina, Inc. is an American company. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets. Its headquarters are located in San Diego, California.
Analyst Target Price
$147.17
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-05 | 2025-10-30 | 2025-07-31 | 2025-05-08 | 2025-02-06 | 2024-11-04 | 2024-08-06 | 2024-05-02 | 2024-02-08 | 2023-11-09 | 2023-08-09 |
| Reported EPS | 1.15 | 1.35 | 1.34 | 1.19 | 0.97 | 0.86 | 1.14 | 0.36 | 0.09 | 0.14 | 0.33 | 0.32 |
| Estimated EPS | 1.06 | 1.23 | 1.17 | 1.01 | 0.94 | 0.92 | 0.88 | 0.9 | 0.11 | 0.12 | 0.14 | 0.02 |
| Surprise | 0.09 | 0.12 | 0.17 | 0.18 | 0.03 | -0.06 | 0.26 | -0.54 | -0.02 | 0.02 | 0.19 | 0.3 |
| Surprise Percentage | 8.4906% | 9.7561% | 14.5299% | 17.8218% | 3.1915% | -6.5217% | 29.5455% | -60% | -18.1818% | 16.6667% | 135.7143% | 1500% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | 1.24 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ILMN
2026-06-11 18:10:13
This article discusses the challenges faced in interpreting genomic data even after successful sequencing, particularly with rare variants or variants of uncertain significance (VUS). It highlights the growing importance of reanalysis, tertiary analysis in oncology, and the integration of broader contextual information and multidisciplinary expertise. The piece also notes the role of AI in streamlining interpretation workflows and introduces Illumina's Grand Rounds in Genomic Medicine webinar series as a platform for sharing knowledge and fostering a global learning community among experts.
2026-06-11 17:25:00
Illumina Inc. (ILMN) saw its stock rise by 2.30% to $166.21 on Thursday, marking its third consecutive day of gains. This performance outpaced the broader market, with the S&P 500 Index increasing by 1.75% and the Dow Jones Industrial Average rising by 1.86%. The strong trading day contributed to Illumina's positive momentum against its competitors.
2026-06-11 14:09:39
Illumina's Q1 2026 results exceeded guidance, driven by strong clinical sequencing demand and NovaSeq X placements, leading to a 22% non-GAAP operating margin. The company raised its full-year operating margin guidance to 23-24%, indicating a significant recovery. Despite trailing some peers, TIKR's mid-case valuation suggests Illumina stock is undervalued, with a potential target of $228 by December 2030, offering a significant return.
2026-06-11 08:09:39
Fox Run Management L.L.C. has acquired a new stake in Illumina, Inc. (NASDAQ:ILMN), purchasing 6,580 shares valued at approximately $863,000 during the fourth quarter. This comes as several analysts have updated their ratings and price targets for Illumina, with a consensus "Hold" rating and an average price target of $142.13. Despite insider selling, Illumina reported stronger-than-expected quarterly results with an EPS of $1.15 on revenue of $1.09 billion.
2026-06-10 17:24:00
Illumina Inc. (ILMN) saw its stock advance 1.52% to $162.47 on a dismal trading day where the S&P 500 and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for Illumina. The article highlights Illumina's strong performance relative to the broader market and its competitors.
2026-06-10 12:48:00
J.P. Morgan has upgraded Illumina (ILMN) stock to Overweight from Neutral and raised its price target to $185 from $125. This upgrade is based on a favorable outlook for the gene sequencing company, following a recent customer survey.
